{"id":"NCT01609010","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of MabThera/Rituxan (Rituximab) Alone and in Combination With Roferon-A in Patients With Follicular or Other CD20+ Low-Grade (Indolent) Lymphoma","officialTitle":"Rituximab (Mabthera®) as Single Agent and in Combination With Interferon Alfa-2a (Roferon-A®), a Phase-III Randomized Trial in Patients With Follicular or Other CD20+ Low-grade (Indolent) Lymphoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-10","primaryCompletion":"2011-07","completion":"2011-07","firstPosted":"2012-05-31","resultsPosted":"2014-06-25","lastUpdate":"2014-09-08"},"enrollment":313,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Lymphoma"],"interventions":[{"type":"DRUG","name":"rituximab","otherNames":["MabThera","Rituxan"]},{"type":"DRUG","name":"interferon-a-2a","otherNames":["Roferon-A"]}],"arms":[{"label":"Rituximab Monotherapy","type":"ACTIVE_COMPARATOR"},{"label":"Rituximab, Interferon","type":"EXPERIMENTAL"}],"summary":"This randomized, open-label study will compare the efficacy and safety of MabThera/Rituxan (rituximab) alone, and in combination with Roferon-A (interferon alfa-2a) in patients with follicular or other CD20+ low-grade lymphoma. Patients will be randomized to receive either MabThera/Rituxan 375 mg/m2 intravenously weekly for 4 weeks or Roferon-A 3 MIU/day subcutaneously in Week 1 followed by 4.5 MIU/day sc in Weeks 2-5 plus MabThera/Rituxan 375 mg/m2 weekly iv in Weeks 3-6. Patients who have a response will receive an additional cycle of treatment. The anticipated time on study treatment is up to 6 months.","primaryOutcome":{"measure":"Treatment Failure - Percentage of Participants With an Event","timeFrame":"Baseline (BL), Week 10 and 16, and Months 6, 12, 18, 24, 30, and 42 of the follow-up period","effectByArm":[{"arm":"Rituximab Monotherapy","deltaMin":68,"sd":null},{"arm":"Rituximab + IFN","deltaMin":67,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":31,"countries":["Denmark","Norway","Sweden"]},"refs":{"pmids":["25686644"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":13,"n":156},"commonTop":["General disorders and ASC","Gastrointestinal disorders","Musculoskeletal and connective tissue disorders","Nervous system disorders","Infections and infestations"]}}